Erschienen in:
01.06.2014 | Laboratory Investigation
MGMT promoter methylation status in clival chordoma
verfasst von:
Gianluca Marucci, Luca Morandi, Diego Mazzatenta, Giorgio Frank, Ernesto Pasquini, Maria Pia Foschini
Erschienen in:
Journal of Neuro-Oncology
|
Ausgabe 2/2014
Einloggen, um Zugang zu erhalten
Abstract
Chordomas are rare, slow-growing neoplasms, characterized by locally aggressive growth patterns and high local recurrence rates. To the best of our knowledge, the MGMT promoter methylation status has not been studied in a population of patients with chordomas to determine if a biologic rationale exists to support the use of temozolomide. We here show for the first time that methylation of MGMT promoter is present in a significant portion or recurring clival chordomas; on the contrary in clival chordomas without recurrence MGMT promoter was always unmethylated (p = 0.0317). Although these observations need to be confirmed in a larger study population, our results (1) indicate that methylation of MGMT promoter is present in a significant portion of recurring chordomas, and (2) prompt further investigation into the potential role of temozolomide as an adjuvant treatment of these tumors.